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BACKGROUND: Although administration of stress ulcer prophylaxis (SUP) has been recommended for specific
patients in the intensive care unit (ICU) setting, this practice has been extrapolated to care of
non-ICU patients without evidence to support need or efficacy.
AIMS: To examine the practice of SUP in non-ICU patients in a university hospital setting, with specific
attention to resource utilization.
METHODS: Retrospective chart review of adult non-ICU admissions to one family medicine and five general
internal medicine teaching services over a consecutive 4-month period. Proportion of patients
prescribed SUP was ascertained after exclusion of patients admitted on antisecretory therapy (AST)
or prescribed AST for non-SUP indications. Annual cost estimates were calculated assuming full
compliance.
RESULTS: Of 1,769 patient admissions, 22% received SUP and 54% of these were discharged home on AST.
None of these patients met evidence-based criteria for appropriate SUP. Inpatient SUP cost $11,024
over the 4 months of the study ($44,096 annually), and outpatient costs based on discharge
prescriptions were $16,924 ($67,695 annually), yielding a total cost expenditure of $27,948
($111,791 annually).
CONCLUSION: SUP is overutilized in the non-ICU setting, and patients are often discharged unnecessarily on AST,
resulting in significant cost expenditure. Interventions to ensure appropriate use of SUP should
decrease resource expenditures without detrimental impact on quality of care.
(Am J Gastroenterol 2006;101:2200–2205)
INTRODUCTION
Stress ulceration is defined as a form of hemorrhagic gastritis
that may occur in patients who have suffered a moderate to
severe physiologically stressful event such as surgery, trauma,
organ failure, sepsis, thermal injury, or prolonged mechanical
ventilation (1). Since not all episodes of microscopic bleed-
ing are clinically relevant, studies using only microscopic
bleeding as an end point artificially inflate the reported fre-
quency of gastrointestinal (GI) bleeding and stress ulceration
(2). Previous studies that have provided estimates of stress
ulceration incidence in the intensive care unit (ICU) setting
may have led providers to consider this potential problem in
patients in non-ICU settings, leading to significant patient
care and cost implications.
The American Society of Health-System Pharmacists
(ASHP) guidelines for stress ulcer prophylaxis (SUP) from
1999 serve as a framework for instituting preventive therapy
in ICU patients. SUP is not recommended for adult general
medical and surgical patients in non-ICU settings with fewer
than two risk factors for clinically important bleeding, or for
patients with two or more risk factors (Table 1). Few studies
to date have effectively examined the role of SUP in non-ICU
patients (3–5). Cost-effectiveness studies in patients receiv-
ing SUP have been limited solely to ICU settings (6–9).
Our hypothesis is that many patients admitted to general
medical and family medicine (non-ICU) services are rou-
tinely placed on antisecretory therapy (AST) for SUP, when
neither the admitting nor the comorbid diagnoses support
their use for either treatment or GI prophylaxis. Moreover,
we suspect that a large percentage of these patients started
on AST for SUP are discharged from the hospital on these
medications. Our goal was to examine the practice of SUP in
non-ICU patients in a university hospital setting, with specific
attention to resource utilization.
METHODS
The University of Michigan Health System is a large, multi-
specialty teaching hospital located in Ann Arbor, Michigan.
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A retrospective chart review was performed of consecutive
adult non-ICU patient admissions to one family medicine
and five general internal medicine teaching services from
January 1 through April 30, 2004, to assess the practice of
SUP. Some patients were admitted multiple times during the
4 months, even to multiple services, and thus each admission
was counted separately. If a patient was transferred to one of
these services as a “step down” from the ICU, then the data
for those hospital days were counted as an admission.
SUP was defined as the prescription of antisecretory med-
ication (histamine-2 receptor antagonist [H2RA] or proton
pump inhibitor [PPI]) for the purpose of preventing GI injury
via stress ulceration. Documentation in the medical record
was required to establish an SUP indication with pharmacy
data to confirm administration of AST. Data collection fo-
cused solely on chart references that specifically stated that
AST was administered, documented under the “Assessment
and Plan” section of the progress notes, and noted specifically
that AST was given for either “stress ulcer prophylaxis” or
“GI prophylaxis.” All patients for whom AST was given for
a specific indication or appropriate treatment purpose were
not counted as having received SUP; patients admitted on
or treated with AST for appropriate GI diagnoses (e.g., gas-
troesophageal reflux disease [GERD], peptic ulcer disease
[PUD], dyspepsia, acute or suspected GI bleeding) were ex-
cluded from the definition of SUP. Of all patient admission
charts reviewed, no single chart mentioned that AST was
given specifically for “NSAID (nonsteroidal antiinflamma-
tory drug) ulcer prophylaxis,” or anything similar to this. If
a patient was admitted on AST and NSAIDs concomitantly,
they were not counted as having received SUP.
For each admission, admitting diagnoses, duration of SUP,
type and number of antisecretory medications used for SUP,
and 30-day prescriptions for antisecretory medications given
on discharge were recorded. Occurrence of GI bleeding or
documentation of stress ulcer was also abstracted from pa-
tient files. Appropriate administration of SUP was defined
by the ASHP guidelines (Table 1). Cost data were based
on the number of pills administered combined with using
average wholesale price data from the Pharmacy Redbook
2004. Annual cost estimates were calculated assuming lin-
ear relationships and full compliance. Comparisons between
study subgroups were performed using bivariate and multi-
variate regression analysis.
RESULTS
Of the 1,769 consecutive patient admissions that occurred
during the 4 months of the study, 585 (33.1%) were already
taking AST on admission, although only 433 (74.0% of those
treated) had a diagnosis listed in the medical record that sup-
ported the use of AST. Seventy-two additional patients had
AST initiated during the admission for therapy of appropri-
ate GI conditions (e.g., GI bleeding, dyspepsia, GERD, PUD).
Three-hundred ninety-one patient admissions (22.1% of to-
tal, 95% confidence interval [CI] 20–24%) were documented
Table 1. Strength of Evidence of Stress Ulcer Prophylaxis for Adult
ICU Patients According to Risk Factor
Risk Factor Strength of Evidence∗
General (medical, surgical,
respiratory) ICU
populations
A (for H2RAs, antacids)
B (for sucralfate)
Head injury with Glasgow
Coma Score of ≤ 10 or
inability to obey simple
commands
B (for H2RAs)
D (for antacids, sucralfate)
Thermal injury involving
>35% of body surface area
B (for antacids)
D (for H2RAs, sucralfate)
Partial hepatectomy C (for H2RAs)
D (for antacids, sucralfate)
Hepatic or renal
transplantation
D (for H2RAs, antacids, sucralfate)
Multiple trauma with Injury
Severity Score of ≥ 16
D (for H2RAs, antacids, sucralfate)
Spinal cord injury D (for H2RAs, antacids, sucralfate)
Hepatic failure D (for H2RAs, antacids, sucralfate)
History of gastric ulceration
or bleeding during 1 yr
prior to admission
D (for H2RAs, antacids, sucralfate)
Presence of at least 2 of the
following:
D (for H2RAs, antacids, sucralfate)
• Sepsis
• ICU stay of greater than 1 wk
• Occult or overt bleeding for ≥ 6 days
• Corticosteroid therapy (>250 mg hydrocortisone
or equivalent daily)
ICU = intensive care unit; H2RAs = histamine-2 receptor antagonists.
∗Evidence levels:
A—Meta-analyses of randomized controlled trials (RCTs) and RCTs with
sufficient sample size to detect a difference of 50% or less in rates of clinically
important bleeding and 95% confidence interval.
B—Meta-analyses of RCTs and RCTs with 95% confidence interval.
C—Nonrandomized concurrent or historic cohort studies and case series.
D—Expert opinion of panel members.
Adapted from: ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Am J
Health-Syst Pharm 1999;56:347–79.
to have received AST for an indication of SUP. None of these
patients met criteria for appropriate SUP according to ASHP
guidelines. Pantoprazole was the most frequently used anti-
secretory medication (89.4% of total pills), followed by rani-
tidine (8.3% of total pills). Twelve percent of our total cohort
was discharged home with a prescription for AST (54.4% of
the population that received SUP) (Fig. 1). There were no sig-
nificant differences in SUP use among the six services. There
was no documentation of stress ulceration in any of the pa-
tients reviewed in this study, including the patients who did
not receive SUP.
Although the most common admitting diagnoses for pa-
tients in our study fell under the category of a GI etiology,
only 15.6% of patients in this diagnostic category received
AST documented as SUP; in contrast, patients admitted with
a rheumatologic diagnosis received the highest percentage of
SUP at 32.1% (Table 2). Compared to patients admitted with a
GI-related diagnosis, patients admitted with diagnoses in the
following categories were significantly more likely to receive
SUP (odds ratio): cardiovascular (2.0), hematologic (1.8),
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Figure 1. Prevalence of stress ulcer prophylaxis in non-ICU patients.
Proportion of consecutive patient admissions over 4-month period
of study in which stress ulcer prophylaxis (SUP) was documented to
have been administered. The subset on the right depicts the propor-
tion administered SUP while as inpatients who were subsequently
discharged on antisecretory therapy. @ D/C = at time of discharge;
ICU = intensive care unit.
orthopedic (2.1), pulmonary (1.8), renal (1.8), and rheuma-
tologic (2.2) (Table 3).
Inpatient SUP costs for the study cohort totaled $11,024
over the 4 months of the study. Assuming constant rates of
SUP prescription, this represents an annual outlay of $44,096
for the six admitting services. Outpatient pharmacy costs to-
taled $16,924 on the basis of the prescriptions given at dis-
charge. Assuming full compliance by patients and a constant
rate of prescription, this results in an annual cost of $67,695.
Total AST costs for the study cohort, combining inpatient and
outpatient medications, equaled $27,948, which represents an
Table 2. Incidence of SUP by Diagnosis
Number of % of % That
Organ System Admissions∗ Total Received SUP†
Gastrointestinal 360 20.3% 15.6%
Infectious diseases 250 14.1% 22.4%
Pulmonary 242 13.7% 27.7%
Cardiovascular 196 11.1% 30.1%
Metabolic 179 10.1% 21.2%
Renal 142 8.0% 30.3%
Neurological 127 7.2% 20.5%
Urologic 115 6.5% 18.3%
Orthopedic 98 5.5% 29.6%
Other‡ 87 4.9% 10.3%
Hematologic 72 4.1% 27.8%
Rheumatologic 53 3.0% 32.1%
Psychologic 30 1.7% 16.7%
∗
Refers to primary diagnosis listed on admission and discharge records for each
patient admission. Note that for some patients, multiple primary diagnoses were listed.
†Reflects patient admissions treated with antisecretory medications as specifically
documented for SUP, not for treatment of disease.
‡Reflects admission and discharge diagnoses listed under the categories: dental,
dermatologic, drug reaction, gynecologic, obstetrical, oncologic, ophthalmologic,
otolaryngologic, and trauma.
Table 3. SUP by Admission Diagnosis
Odds Ratio 95% Confidence Interval
Cardiology 2.0 1.4–2.9
Endocrinology 0.3 .04–2.3
Hematology 1.8 1.1–3.2
Metabolism 1.3 0.9–2.0
Infectious disease 1.4 0.9–2.0
Neurology 1.2 0.8–2.0
Orthopedic 2.1 1.3–3.5
Pulmonary 1.8 1.2–2.5
Psychiatry 1.0 0.4–2.7
Renal 1.8 1.2–2.7
Rheumatology 2.2 1.2–4.1
Urology 1.1 0.6–1.8
Other 0.6 0.3–1.2
SUP = stress ulcer prophylaxis.
Other—dental, dermatologic, drug reaction, gynecologic, obstetrical, oncologic,
ophthalmologic, otolaryngologic, and trauma.
annual total cost for AST prescribed for unnecessary SUP of
$111,791 (Fig. 2).
DISCUSSION
Despite a lack of evidence supporting its use, this study re-
vealed that 22.1% of hospitalized non-ICU patients were
routinely prescribed SUP. More disturbingly, the majority
of these patients (54.4%) unnecessarily continued AST in
the outpatient setting. This practice resulted in substantial
cost expenditure that could be avoided. While guidelines
for SUP in ICU patients have been well defined in the
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Figure 2. Cost of stress ulcer prophylaxis in non-ICU patients. Cost
of stress ulcer prophylaxis (SUP) based on pharmacy expenditures
for the six admitting services examined in this report. Data are sep-
arated by costs incurred as inpatient (based on inpatient pharmacy
records) and outpatient (based on discharge medication prescrip-
tions), as well as by total costs. Annualized data assume that a con-
stant proportion of patients are prescribed SUP, and that patients are
fully compliant with medication. ICU = intensive care unit.
Inappropriate Use of Stress Ulcer Prophylaxis 2203
medical literature, the perceived benefit from SUP has been
extrapolated to patients in non-ICU settings (assuming simi-
lar criteria and similar appropriate guidelines), leading to an
excessive consumption of these medications and increased
overall cost.
Our study highlights the common practice of nonindicated
SUP use, as well as the high rate of AST without documented
indication among patients admitted to non-ICU wards. There
was no difference among admitting specialties; therefore, this
likely represents a systematic practice not limited to one ser-
vice. Interestingly, patients admitted with a primary GI di-
agnosis were less likely to receive SUP than several other
diagnostic categories, notably patients admitted with rheuma-
tologic disorders, who were 2.2 times more likely to receive
SUP. Although this may represent a higher use of potentially
ulcerogenic medication among patients with non-GI diag-
noses, the medical record documentation stated use of AST
for SUP as opposed to chemoprevention against GI toxicity
due to concomitant medication use.
One reason for the widespread use of SUP may be the low
rate of side effects associated with these medications. Most
adverse effects attributable to antacids, H2RAs, and sucralfate
are uncommon and occur in less than 1% of adult patients,
particularly when given for a period of less than 2 wk (2).
Rare adverse side effects include aluminum and magnesium
toxicity, vitamin B12 deficiency, and nosocomial pneumonia.
However, it has been noted that H2RAs and PPIs have the
potential for drug–drug, drug–nutrient, and drug–test inter-
actions through a variety of mechanisms (2). The frequency
and severity of adverse effects may increase in renal fail-
ure, in the elderly, and in malnourished patients, secondary
to electrolyte accumulation due to antacid administration or
central nervous system disturbances due to administration of
H2RAs. Reduction of gastric acid secretion by AST may in-
crease the risk of community-acquired pneumonia. A large
case-controlled study found that patients taking H2RAs had
a 1.63-fold increased risk of developing pneumonia (95%
CI) compared with those who stopped AST (10). For patients
taking PPIs, a significant positive dose–response relationship
was observed, while for current H2RA users, the variation
in dose was restricted. Conversely, a randomized, yet much
smaller study determined that the rate of the development of
nosocomial pneumonia in 158 mechanically ventilated pa-
tients in a surgical ICU was not adversely affected by the
administration of H2RAs for SUP (11).
Controversy exists over the use of pharmacologically in-
duced acid suppression in critically ill patients at risk for
stress ulcers. The ASHP guideline does not include recom-
mendations on the use of PPIs for SUP, yet we suspect they
may be the most frequently used acid-suppressive medica-
tions for SUP. This guideline recommends that the choice
among antisecretory agents for SUP in adult patients admit-
ted to general medical and surgical ICUs should be made on
an institution-specific basis. Expert opinion states that this
choice should take into account concerns regarding adminis-
tration, adverse-effect profile, and total costs (2). One review
summarized that PPIs are both safe and efficacious for elevat-
ing intragastric pH in critically ill patients, and should be used
only as an alternative to H2RAs or sucralfate, since the supe-
riority of PPIs over these agents for preventing stress ulcers
has not been established (12). Additional comparative stud-
ies with adequate patient numbers and pharmacoeconomic
analyses are needed before PPIs are considered the agents of
choice for SUP in either ICU or non-ICU settings (13).
On the basis of the potential adverse events, SUP prophy-
laxis is not warranted in patients at low risk for clinically im-
portant bleeding (e.g., patients not receiving mechanical ven-
tilation, or those without significant coagulopathy); the num-
ber needed to treat (NNT) is greater than 900 such patients
to prevent a single episode of clinically significant GI bleed-
ing (14). ASHP guidelines highlight a study of 100 adults on
a general medical and surgical hospital ward in Barcelona,
Spain. Their results revealed that the frequency of all types of
clinically important GI bleeding was significantly lower with
prophylaxis using antacids, but only if two or more risk fac-
tors for bleeding were present prior to the initiation of SUP
(15). One study of 293 patients with chronic renal failure on
dialysis revealed a 41% utilization rate of AST for SUP, and
in 63% of cases, there was no adequate indication (16).
Two studies published since the release of the ASHP guide-
lines reported significant overuse of SUP in non-ICU patients.
Nardino et al. reviewed 226 patients admitted to a general
adult medicine service in a community hospital and found
that 54% of patients received AST, most commonly H2RAs
(62% of total), yet 65% of prescriptions were not indicated
as determined by consensus review. Among the 54% of pa-
tients who received SUP, 55% were discharged home on the
therapy (4). Similar to our findings, Zink et al. reviewed 814
general adult medicine admissions in a community hospital
setting, of which 324 were given SUP (40% of total). They
noted that 40% of patients receiving SUP were actually given
AST for an appropriate medical indication (thus not SUP),
while 60% were not. The most frequently cited reason for
prescribing AST without an indication was “GI prophylaxis,”
yet a major limitation of this study was that acceptable indi-
cations for acid suppression were not recorded. Thirty-four
percent of patients in that study who received SUP were dis-
charged home on the acid-suppressive medication on which
they were started (5). Resource utilization was not reported
in these studies.
Resource utilization data regarding SUP trends in the ICU
setting have been published. A study performed at the Car-
olinas Medical Center found an estimated annual savings
of $102,895 in patient charges and $11,333 in actual drug
costs in a trauma ICU attributable to the implementation of
SUP guidelines (6). Another ICU-based study performed
in a tertiary-care teaching hospital in Vancouver, British
Columbia, Canada concluded that after the introduction of
a guideline for SUP administration, appropriateness of ther-
apy increased from 75.8% to 91.1%, and medication costs de-
creased from C $2.50/day to C $1.30/day without any statisti-
cally significant difference in clinical outcomes. Introduction
2204 Heidelbaugh and Inadomi
of this guideline was associated with an increase in appro-
priateness of prophylaxis and a decrease in medication costs
(7).
Since the data in our study were abstracted by chart re-
view from each patient hospitalization, it is possible that GI
symptoms may not have been reported and/or documented
in the patient chart. Ultimately, we suspect that the reported
incidence data for SUP in our study may be artificially low,
which is commensurate with the Nardino et al. and Zink
et al. studies. The cost analysis was limited to the actual
amount of medication dispensed by the pharmacy during the
hospitalization, and the prescriptions written for the patient
at the time of discharge. Extrapolation to estimate annual cost
expenditures for the cohort was based on assumptions that a
constant proportion of patients were administered SUP as in-
patients and discharged on AST. One potentially confounding
factor in our cost analysis was that we assumed full compli-
ance with obtaining prescriptions for AST on discharge from
the hospital. In retrospect, to potentially be more accurate,
we could have followed each of these patient admissions to
determine if they in fact filled the prescriptions for AST and if
they continued on AST unnecessarily over time. Therefore,
annualized cost estimates may deviate from actual costs if
the 4-month period of study was not representative of usual
practice, or if patients did not adhere to prescribed medi-
cation as outpatients. All admitting services had numerous
attending and resident physicians rotating coverage through-
out the 4 months of the study, and there were also residents
who covered more than one service. Thus, this appears to be a
systematic issue not limited to a particular group of residents
or faculty.
Our impression is that the practice of SUP in the non-
ICU setting may be somewhat reflexive, extrapolated from
common practice in the ICU setting. This hypothesis stems
from an idea that physicians may feel that certain non-ICU
patients are at a higher risk of developing stress ulcers (i.e.,
those patients on chronic or high-dose steroids, patients who
are septic or potentially septic, etc.), and that a relatively
simple intervention of using AST would provide minimal
patient risk and safeguard against stress ulceration, without
clear regard for cost-effective provisions of care. No data
currently exist on stress ulceration rates in non-ICU patients;
data from ICU populations are widely variable and not ap-
plicable to this study. We feel that it is reasonable, however,
for clinician judgment to determine if a patient with mod-
erate to severe physiologic stress (i.e., the use of chronic or
high-dose steroids, sepsis, or potential sepsis, etc.) in the non-
ICU setting may ultimately benefit from AST for SUP, taking
into consideration potential risks versus benefits, likelihood
of stress ulcer development, cost-effectiveness, and certainly
a plan for ensuring that patients are not discharged on AST
without appropriate symptoms or indication for treatment.
Potential interventions to minimize inappropriate use of
SUP in the non-ICU setting include (i) the use of the ASHP
guidelines (albeit from 1999) in non-ICU patients (perhaps
there will eventually be updated guidelines with solid [or even
expert opinion] recommendations but, to date, no such update
is currently under way), (ii) adaptation of these or very sim-
ilar guidelines for institutions that are readily accessible and
could be easily referenced, and (iii) appropriate instruction
of resident and junior attending physicians in this practice as
a model for cost-effectiveness of care. Overuse of resources
is compounded by the frequent practice of continuing non-
indicated AST after discharge. Provider education regarding
proper implementation of SUP may lead to substantial re-
ductions in health-care costs without impairment of patient
outcome. As there are wide variations in prescribing practices
for both non-ICU and ICU SUP, we reiterate previous recom-
mendations that institutions consult published literature and
use preexisting guidelines as templates for the development
of their own institutional guidelines (2,17). Future updated
ASHP guidelines on SUP may address both the role of PPIs
and resource utilization.
STUDY HIGHLIGHTS
What Is Current Knowledge Stress ulcer prophylaxis may be indicated in certain
ICU patients.
What Is New Here Stress ulcer prophylaxis is overutilized in the non-ICU
setting. There is a lack of solid evidence to support stress ulcer
prophylaxis in the non-ICU setting. Patients are often discharged unnecessarily on antise-
cretory therapy. Ensuring appropriate use of stress ulcer prophylaxis
should decrease resource expenditures.
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